XSpray Pharma AB (XSPRAY) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.054x

Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has a cash flow conversion efficiency ratio of -0.054x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-30.68 Million ≈ $-3.30 Million USD) by net assets (Skr569.36 Million ≈ $61.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See XSPRAY net asset quality index to measure how much of total assets are equity-financed.

XSpray Pharma AB - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how XSpray Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of XSpray Pharma AB to evaluate the quality of earnings relative to operating cash generation.

XSpray Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of XSpray Pharma AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Her Chee Industrial Co Ltd TWO:8937	-0.012x
Ten Ren Tea Co Ltd TW:1233	0.050x
FM Global Logistics Holdings Bhd KLSE:7210	0.028x
Tambun Indah Land Bhd KLSE:5191	0.005x
Popular Vehicles and Services Limited NSE:PVSL	-0.018x
Jung Shing Wire Co Ltd TW:1617	-0.018x
Groupe Minoteries SA SW:GMI	0.015x
Hanjin Heavy Ind & Const Holdings Co Ltd KO:003480	0.039x

Annual Cash Flow Conversion Efficiency for XSpray Pharma AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of XSpray Pharma AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see XSpray Pharma AB market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr604.65 Million ≈ $65.07 Million	Skr-193.16 Million ≈ $-20.79 Million	-0.319x	+10.48%
2024-12-31	Skr623.10 Million ≈ $67.06 Million	Skr-222.37 Million ≈ $-23.93 Million	-0.357x	-21.74%
2023-12-31	Skr693.41 Million ≈ $74.62 Million	Skr-203.28 Million ≈ $-21.88 Million	-0.293x	-47.94%
2022-12-31	Skr556.02 Million ≈ $59.84 Million	Skr-110.18 Million ≈ $-11.86 Million	-0.198x	-127.22%
2021-12-31	Skr591.75 Million ≈ $63.68 Million	Skr-51.61 Million ≈ $-5.55 Million	-0.087x	-6.31%
2020-12-31	Skr582.59 Million ≈ $62.70 Million	Skr-47.79 Million ≈ $-5.14 Million	-0.082x	+10.46%
2019-12-31	Skr373.71 Million ≈ $40.22 Million	Skr-34.24 Million ≈ $-3.68 Million	-0.092x	-55.76%
2018-12-31	Skr301.72 Million ≈ $32.47 Million	Skr-17.75 Million ≈ $-1.91 Million	-0.059x	+17.07%
2017-12-31	Skr155.66 Million ≈ $16.75 Million	Skr-11.04 Million ≈ $-1.19 Million	-0.071x	-89.00%
2016-12-31	Skr46.47 Million ≈ $5.00 Million	Skr-1.74 Million ≈ $-187.68K	-0.038x	+96.45%
2015-12-31	Skr12.26 Million ≈ $1.32 Million	Skr-12.96 Million ≈ $-1.40 Million	-1.057x	--

About XSpray Pharma AB

ST:XSPRAY Sweden Biotechnology

Market Cap

$82.56 Million

Skr767.20 Million SEK

Market Cap Rank

#19833 Global

#352 in Sweden

Share Price

Skr16.18

Change (1 day)

-4.15%

52-Week Range

Skr14.50 - Skr63.40

All Time High

Skr258.00